A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 12 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Sep 2012 Planned End Date changed from 1 Jun 2012 to 1 Nov 2014 as reported by Clinicaltrials.gov.
- 17 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov.